Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences
No data are available on HIV/hepatitis B virus (HBV) or hepatitis C virus coinfection in Togo, and patients are not routinely tested for HBV infection. To determine the prevalence of HBV and the risk of HBV drug resistance during antiretroviral treatment in HIV-coinfected patients in Togo. This cro...
Gespeichert in:
| Veröffentlicht in: | SAMJ: South African Medical Journal 2016-06, Vol.106 (6), p.634-639 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 639 |
|---|---|
| container_issue | 6 |
| container_start_page | 634 |
| container_title | SAMJ: South African Medical Journal |
| container_volume | 106 |
| creator | Patassi, Akouda Benaboud, Sihem Landoh, Dadja Essoya Salou, M Dagnra, Anoumou Claver Saka, Bayaki Krivine, Anne Meritet, Jean-François Pitché, Palokinam Salmon-Ceron, Dominique |
| description | No data are available on HIV/hepatitis B virus (HBV) or hepatitis C virus coinfection in Togo, and patients are not routinely tested for HBV infection.
To determine the prevalence of HBV and the risk of HBV drug resistance during antiretroviral treatment in HIV-coinfected patients in Togo.
This cross-sectional study was carried out in Lomé, Togo, from January 2010 to December 2011 among HIV-infected patients who had been on antiretroviral therapy (ART) for at least 6 months.
In total, 1 212 patients (74.9% female) living with HIV/AIDS and treated with ART were included in the study. The seroprevalence of hepatitis B surface antigen (HBsAg) was 9.7% (117/1 212; 95% confidence interval (CI) 8.04 - 11.45). Of these 117 HBsAg-positive patients, 16 (13.7%) were hepatitis B e-antigen (HBeAg)-positive, and 115 (98.3%) were on lamivudine. The HBV DNA load was >10 IU/mL in 33/117 patients overall (38%), and in 87.5% of 16 HBeAg-positive patients (p10 IU/mLwere HBeAg positivity (adjusted odds ratio (aOR) 6.4; p=0.001) and a higher level of education (aOR 6.5; p=0.026). The prevalence of HBV resistance to lamivudine was 13.0% (15/115; 95% CI 7.0 - 19.0). The detected resistance mutations were rtL180M (14/15 patients) and rtM204V/I (15/15).
The seroprevalence of HBV among ART-treated HIV-infected patients in Togo was 9.7%. The prevalence of HBV lamivudine resistance mutations after 2 years of ART was 13.0%. These results suggest that HBV screening before ART initiation can be based on HBsAg testing. |
| doi_str_mv | 10.7196/SAMJ.2016.v106i6.10312 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_sciel</sourceid><recordid>TN_cdi_scielo_journals_S0256_95742016000600033</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A454485733</galeid><scielo_id>S0256_95742016000600033</scielo_id><sourcerecordid>A454485733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c363t-5954409f022302866e111616961cd549610622aff2ce4a103ccc7bdc0132fc833</originalsourceid><addsrcrecordid>eNpVUu1u0zAUtRCIlcIrTJaQED9I8UfiNPwrE9ChIpA2-Gt5zk3ryYk726nUB-EheA5eDJsMtMqy_HXO9b3nHoTOKVnUtBFvr1ZfPi8YoWJxoEQYsaCEU_YIzRipl0VFefUYzQirRNFUdXmGnoVwS9K5asRTdMZqVlY1L2fo5xr2KppoAn6PzdCBjsYNaYfXlz8KWkxX0OKMgiEG7EGDOZhhi3dmu7NHrBLlAFgN0XiI3h2MVxbHHXi1P-ZIG9f__vUGX7ute4e_eTgoC4POjBb3zoIerfJYuyHA3ZhfwnP0pFM2wIv7dY6-f_xwfbEuNl8_XV6sNoXmgseiaqqyJE1HGOOELYUASqmgohFUt1WZFiIYU13HNJQqKaS1rm9aTShnnV5yPkeLKW7QBqyTt270Q_pQXmXpZJYua0wIyZNnwuuJsPcu5Rqi7E3QYK0awI1B0rrhlViK1IA5ejlBt6lcmXR00Sud4XJVpryXqQEPMjhBpdFCb5Ik0Jl0f0J49YCwA2XjLjg75raFU6CYgNq7EDx0cu9Nr_xRUiKzh2T2kMz1yclD8q-HEvH8vsbxpof2P-2fafgf9A3AFQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1793568651</pqid></control><display><type>article</type><title>Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences</title><source>DOAJ Directory of Open Access Journals</source><source>African Journals Online (Open Access)</source><source>Sabinet African Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Patassi, Akouda ; Benaboud, Sihem ; Landoh, Dadja Essoya ; Salou, M ; Dagnra, Anoumou Claver ; Saka, Bayaki ; Krivine, Anne ; Meritet, Jean-François ; Pitché, Palokinam ; Salmon-Ceron, Dominique</creator><creatorcontrib>Patassi, Akouda ; Benaboud, Sihem ; Landoh, Dadja Essoya ; Salou, M ; Dagnra, Anoumou Claver ; Saka, Bayaki ; Krivine, Anne ; Meritet, Jean-François ; Pitché, Palokinam ; Salmon-Ceron, Dominique</creatorcontrib><description>No data are available on HIV/hepatitis B virus (HBV) or hepatitis C virus coinfection in Togo, and patients are not routinely tested for HBV infection.
To determine the prevalence of HBV and the risk of HBV drug resistance during antiretroviral treatment in HIV-coinfected patients in Togo.
This cross-sectional study was carried out in Lomé, Togo, from January 2010 to December 2011 among HIV-infected patients who had been on antiretroviral therapy (ART) for at least 6 months.
In total, 1 212 patients (74.9% female) living with HIV/AIDS and treated with ART were included in the study. The seroprevalence of hepatitis B surface antigen (HBsAg) was 9.7% (117/1 212; 95% confidence interval (CI) 8.04 - 11.45). Of these 117 HBsAg-positive patients, 16 (13.7%) were hepatitis B e-antigen (HBeAg)-positive, and 115 (98.3%) were on lamivudine. The HBV DNA load was >10 IU/mL in 33/117 patients overall (38%), and in 87.5% of 16 HBeAg-positive patients (p<0.0001). In multivariate analysis, factors associated with HBV DNA load >10 IU/mLwere HBeAg positivity (adjusted odds ratio (aOR) 6.4; p=0.001) and a higher level of education (aOR 6.5; p=0.026). The prevalence of HBV resistance to lamivudine was 13.0% (15/115; 95% CI 7.0 - 19.0). The detected resistance mutations were rtL180M (14/15 patients) and rtM204V/I (15/15).
The seroprevalence of HBV among ART-treated HIV-infected patients in Togo was 9.7%. The prevalence of HBV lamivudine resistance mutations after 2 years of ART was 13.0%. These results suggest that HBV screening before ART initiation can be based on HBsAg testing.</description><identifier>ISSN: 0256-9574</identifier><identifier>ISSN: 2078-5135</identifier><identifier>EISSN: 2078-5135</identifier><identifier>DOI: 10.7196/SAMJ.2016.v106i6.10312</identifier><identifier>PMID: 27245734</identifier><language>eng</language><publisher>South Africa: Health & Medical Publishing Group</publisher><subject>Analysis ; Comorbidity ; Drug therapy ; Health aspects ; Health Care Sciences & Services ; Health Policy & Services ; Hepatitis B ; Highly active antiretroviral therapy ; HIV (Viruses) ; Medical Ethics ; Medicine, General & Internal ; Medicine, Legal ; Medicine, Research & Experimental ; Prevalence studies (Epidemiology) ; Risk factors</subject><ispartof>SAMJ: South African Medical Journal, 2016-06, Vol.106 (6), p.634-639</ispartof><rights>COPYRIGHT 2016 Health & Medical Publishing Group</rights><rights>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c363t-5954409f022302866e111616961cd549610622aff2ce4a103ccc7bdc0132fc833</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,861,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27245734$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Patassi, Akouda</creatorcontrib><creatorcontrib>Benaboud, Sihem</creatorcontrib><creatorcontrib>Landoh, Dadja Essoya</creatorcontrib><creatorcontrib>Salou, M</creatorcontrib><creatorcontrib>Dagnra, Anoumou Claver</creatorcontrib><creatorcontrib>Saka, Bayaki</creatorcontrib><creatorcontrib>Krivine, Anne</creatorcontrib><creatorcontrib>Meritet, Jean-François</creatorcontrib><creatorcontrib>Pitché, Palokinam</creatorcontrib><creatorcontrib>Salmon-Ceron, Dominique</creatorcontrib><title>Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences</title><title>SAMJ: South African Medical Journal</title><addtitle>S Afr Med J</addtitle><description>No data are available on HIV/hepatitis B virus (HBV) or hepatitis C virus coinfection in Togo, and patients are not routinely tested for HBV infection.
To determine the prevalence of HBV and the risk of HBV drug resistance during antiretroviral treatment in HIV-coinfected patients in Togo.
This cross-sectional study was carried out in Lomé, Togo, from January 2010 to December 2011 among HIV-infected patients who had been on antiretroviral therapy (ART) for at least 6 months.
In total, 1 212 patients (74.9% female) living with HIV/AIDS and treated with ART were included in the study. The seroprevalence of hepatitis B surface antigen (HBsAg) was 9.7% (117/1 212; 95% confidence interval (CI) 8.04 - 11.45). Of these 117 HBsAg-positive patients, 16 (13.7%) were hepatitis B e-antigen (HBeAg)-positive, and 115 (98.3%) were on lamivudine. The HBV DNA load was >10 IU/mL in 33/117 patients overall (38%), and in 87.5% of 16 HBeAg-positive patients (p<0.0001). In multivariate analysis, factors associated with HBV DNA load >10 IU/mLwere HBeAg positivity (adjusted odds ratio (aOR) 6.4; p=0.001) and a higher level of education (aOR 6.5; p=0.026). The prevalence of HBV resistance to lamivudine was 13.0% (15/115; 95% CI 7.0 - 19.0). The detected resistance mutations were rtL180M (14/15 patients) and rtM204V/I (15/15).
The seroprevalence of HBV among ART-treated HIV-infected patients in Togo was 9.7%. The prevalence of HBV lamivudine resistance mutations after 2 years of ART was 13.0%. These results suggest that HBV screening before ART initiation can be based on HBsAg testing.</description><subject>Analysis</subject><subject>Comorbidity</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>Health Care Sciences & Services</subject><subject>Health Policy & Services</subject><subject>Hepatitis B</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV (Viruses)</subject><subject>Medical Ethics</subject><subject>Medicine, General & Internal</subject><subject>Medicine, Legal</subject><subject>Medicine, Research & Experimental</subject><subject>Prevalence studies (Epidemiology)</subject><subject>Risk factors</subject><issn>0256-9574</issn><issn>2078-5135</issn><issn>2078-5135</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVUu1u0zAUtRCIlcIrTJaQED9I8UfiNPwrE9ChIpA2-Gt5zk3ryYk726nUB-EheA5eDJsMtMqy_HXO9b3nHoTOKVnUtBFvr1ZfPi8YoWJxoEQYsaCEU_YIzRipl0VFefUYzQirRNFUdXmGnoVwS9K5asRTdMZqVlY1L2fo5xr2KppoAn6PzdCBjsYNaYfXlz8KWkxX0OKMgiEG7EGDOZhhi3dmu7NHrBLlAFgN0XiI3h2MVxbHHXi1P-ZIG9f__vUGX7ute4e_eTgoC4POjBb3zoIerfJYuyHA3ZhfwnP0pFM2wIv7dY6-f_xwfbEuNl8_XV6sNoXmgseiaqqyJE1HGOOELYUASqmgohFUt1WZFiIYU13HNJQqKaS1rm9aTShnnV5yPkeLKW7QBqyTt270Q_pQXmXpZJYua0wIyZNnwuuJsPcu5Rqi7E3QYK0awI1B0rrhlViK1IA5ejlBt6lcmXR00Sud4XJVpryXqQEPMjhBpdFCb5Ik0Jl0f0J49YCwA2XjLjg75raFU6CYgNq7EDx0cu9Nr_xRUiKzh2T2kMz1yclD8q-HEvH8vsbxpof2P-2fafgf9A3AFQ</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Patassi, Akouda</creator><creator>Benaboud, Sihem</creator><creator>Landoh, Dadja Essoya</creator><creator>Salou, M</creator><creator>Dagnra, Anoumou Claver</creator><creator>Saka, Bayaki</creator><creator>Krivine, Anne</creator><creator>Meritet, Jean-François</creator><creator>Pitché, Palokinam</creator><creator>Salmon-Ceron, Dominique</creator><general>Health & Medical Publishing Group</general><general>Health and Medical Publishing Group</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>GPN</scope></search><sort><creationdate>20160601</creationdate><title>Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences</title><author>Patassi, Akouda ; Benaboud, Sihem ; Landoh, Dadja Essoya ; Salou, M ; Dagnra, Anoumou Claver ; Saka, Bayaki ; Krivine, Anne ; Meritet, Jean-François ; Pitché, Palokinam ; Salmon-Ceron, Dominique</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c363t-5954409f022302866e111616961cd549610622aff2ce4a103ccc7bdc0132fc833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analysis</topic><topic>Comorbidity</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>Health Care Sciences & Services</topic><topic>Health Policy & Services</topic><topic>Hepatitis B</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV (Viruses)</topic><topic>Medical Ethics</topic><topic>Medicine, General & Internal</topic><topic>Medicine, Legal</topic><topic>Medicine, Research & Experimental</topic><topic>Prevalence studies (Epidemiology)</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patassi, Akouda</creatorcontrib><creatorcontrib>Benaboud, Sihem</creatorcontrib><creatorcontrib>Landoh, Dadja Essoya</creatorcontrib><creatorcontrib>Salou, M</creatorcontrib><creatorcontrib>Dagnra, Anoumou Claver</creatorcontrib><creatorcontrib>Saka, Bayaki</creatorcontrib><creatorcontrib>Krivine, Anne</creatorcontrib><creatorcontrib>Meritet, Jean-François</creatorcontrib><creatorcontrib>Pitché, Palokinam</creatorcontrib><creatorcontrib>Salmon-Ceron, Dominique</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SciELO</collection><jtitle>SAMJ: South African Medical Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Patassi, Akouda</au><au>Benaboud, Sihem</au><au>Landoh, Dadja Essoya</au><au>Salou, M</au><au>Dagnra, Anoumou Claver</au><au>Saka, Bayaki</au><au>Krivine, Anne</au><au>Meritet, Jean-François</au><au>Pitché, Palokinam</au><au>Salmon-Ceron, Dominique</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences</atitle><jtitle>SAMJ: South African Medical Journal</jtitle><addtitle>S Afr Med J</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>106</volume><issue>6</issue><spage>634</spage><epage>639</epage><pages>634-639</pages><issn>0256-9574</issn><issn>2078-5135</issn><eissn>2078-5135</eissn><abstract>No data are available on HIV/hepatitis B virus (HBV) or hepatitis C virus coinfection in Togo, and patients are not routinely tested for HBV infection.
To determine the prevalence of HBV and the risk of HBV drug resistance during antiretroviral treatment in HIV-coinfected patients in Togo.
This cross-sectional study was carried out in Lomé, Togo, from January 2010 to December 2011 among HIV-infected patients who had been on antiretroviral therapy (ART) for at least 6 months.
In total, 1 212 patients (74.9% female) living with HIV/AIDS and treated with ART were included in the study. The seroprevalence of hepatitis B surface antigen (HBsAg) was 9.7% (117/1 212; 95% confidence interval (CI) 8.04 - 11.45). Of these 117 HBsAg-positive patients, 16 (13.7%) were hepatitis B e-antigen (HBeAg)-positive, and 115 (98.3%) were on lamivudine. The HBV DNA load was >10 IU/mL in 33/117 patients overall (38%), and in 87.5% of 16 HBeAg-positive patients (p<0.0001). In multivariate analysis, factors associated with HBV DNA load >10 IU/mLwere HBeAg positivity (adjusted odds ratio (aOR) 6.4; p=0.001) and a higher level of education (aOR 6.5; p=0.026). The prevalence of HBV resistance to lamivudine was 13.0% (15/115; 95% CI 7.0 - 19.0). The detected resistance mutations were rtL180M (14/15 patients) and rtM204V/I (15/15).
The seroprevalence of HBV among ART-treated HIV-infected patients in Togo was 9.7%. The prevalence of HBV lamivudine resistance mutations after 2 years of ART was 13.0%. These results suggest that HBV screening before ART initiation can be based on HBsAg testing.</abstract><cop>South Africa</cop><pub>Health & Medical Publishing Group</pub><pmid>27245734</pmid><doi>10.7196/SAMJ.2016.v106i6.10312</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0256-9574 |
| ispartof | SAMJ: South African Medical Journal, 2016-06, Vol.106 (6), p.634-639 |
| issn | 0256-9574 2078-5135 2078-5135 |
| language | eng |
| recordid | cdi_scielo_journals_S0256_95742016000600033 |
| source | DOAJ Directory of Open Access Journals; African Journals Online (Open Access); Sabinet African Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Analysis Comorbidity Drug therapy Health aspects Health Care Sciences & Services Health Policy & Services Hepatitis B Highly active antiretroviral therapy HIV (Viruses) Medical Ethics Medicine, General & Internal Medicine, Legal Medicine, Research & Experimental Prevalence studies (Epidemiology) Risk factors |
| title | Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lomé, Togo: Prevalence and molecular consequences |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T19%3A25%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_sciel&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20B%20infection%20in%20HIV-1-infected%20patients%20receiving%20highly%20active%20antiretroviral%20therapy%20in%20Lom%C3%A9,%20Togo:%20Prevalence%20and%20molecular%20consequences&rft.jtitle=SAMJ:%20South%20African%20Medical%20Journal&rft.au=Patassi,%20Akouda&rft.date=2016-06-01&rft.volume=106&rft.issue=6&rft.spage=634&rft.epage=639&rft.pages=634-639&rft.issn=0256-9574&rft.eissn=2078-5135&rft_id=info:doi/10.7196/SAMJ.2016.v106i6.10312&rft_dat=%3Cgale_sciel%3EA454485733%3C/gale_sciel%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1793568651&rft_id=info:pmid/27245734&rft_galeid=A454485733&rft_scielo_id=S0256_95742016000600033&rfr_iscdi=true |